{"id":4778,"date":"2026-02-18T21:56:54","date_gmt":"2026-02-18T21:56:54","guid":{"rendered":"https:\/\/fehv.org\/?p=4778"},"modified":"2026-02-18T21:56:56","modified_gmt":"2026-02-18T21:56:56","slug":"new-drugs-for-weight-loss","status":"publish","type":"post","link":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/","title":{"rendered":"New drugs for weight loss"},"content":{"rendered":"\n<p style=\"font-size:18px\">There are different liver diseases, one of which is fatty liver, which affects 30% of the population worlwide. Of patients diagnosed with fatty liver disease, 70% are overweight or obese, so one of the strategies for improving this disease would be weight loss.There are several weight loss drugs on the market, always to be taken under medical supervision (Ozempic, Wegovy, Mounjaro). <\/p>\n\n\n\n<p style=\"font-size:18px\">These drugs must be administered by subcutaneous injection, which <strong>can limit the start of treatment and adherence to it<\/strong>, as most patients prefer oral medication to injectable ones. In this regard, the oral use of a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1), called Orforglipron (OR), is being investigated as a treatment for obesity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading mt-5 mb-4\" id=\"h-study-results-in-patient-groups\"><strong>Study results in patient groups<\/strong><\/h2>\n\n\n\n<p style=\"font-size:18px\">An article published in <strong><a href=\"https:\/\/www.nejm.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">The New England Journal of Medicine<\/a><\/strong> studied the Orforglipron for the treatment of obesity. This study included 3,127 overweight patients with a body mass index greater than 27 who did not suffer from any type of diabetes. They were divided into four groups and administered Ooforglipron or placebo (group I: 6 mg, group II: 12 mg, group III: 36 mg, and group IV: placebo) orally every day for 72 weeks. Between 93% and 96.5% of the patients included completed the treatment, as this drug causes side effects such as nausea, constipation, diarrhea, and more. In the case of <strong>patients treated with Orforglipron, weight loss was between 7.5% and 11.2%<\/strong>, compared to 2.1% of those treated with placebo.<\/p>\n\n\n\n<p style=\"font-size:18px\">We can conclude from this study that Orforglipron is a useful weight loss drug for patients who do not want to receive subcutaneous injections. <strong><a href=\"\/en\/especialista\/vicente-carreno\/\">Dr. Carre\u00f1o<\/a><\/strong> and the Foundation\u00b4s doctors agree that this drug can be administered to many patients, but it would be advisable to compare its efficacy with other currently available injectable drugs, such as Ozempic, Wegovy, or Mounjaro.<\/p>\n","protected":false},"excerpt":{"rendered":"Orforglipron, an oral GLP-1 small molecule, shows significant weight loss results and may become an alternative to injectable drugs like Ozempic or Wegovy.","protected":false},"author":1,"featured_media":4776,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[917,621],"tags":[],"class_list":["post-4778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.7 (Yoast SEO v23.7) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New drugs for weight loss - Cl\u00ednica FEHV<\/title>\n<meta name=\"description\" content=\"Orforglipron for obesity is a new oral GLP-1 alternative that achieves significant weight loss without the need for injections.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New drugs for weight loss\" \/>\n<meta property=\"og:description\" content=\"Orforglipron for obesity is a new oral GLP-1 alternative that achieves significant weight loss without the need for injections.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/\" \/>\n<meta property=\"og:site_name\" content=\"Cl\u00ednica FEHV\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/Fundacion%20Para%20el%20Estudio%20de%20las%20Hepatitis%20Virales\/228605694153917\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-18T21:56:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-18T21:56:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ifranco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ifranco\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/\"},\"author\":{\"name\":\"ifranco\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777\"},\"headline\":\"New drugs for weight loss\",\"datePublished\":\"2026-02-18T21:56:54+00:00\",\"dateModified\":\"2026-02-18T21:56:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/\"},\"wordCount\":295,\"publisher\":{\"@id\":\"https:\/\/fehv.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg\",\"articleSection\":[\"Health\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/\",\"url\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/\",\"name\":\"New drugs for weight loss - Cl\u00ednica FEHV\",\"isPartOf\":{\"@id\":\"https:\/\/fehv.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg\",\"datePublished\":\"2026-02-18T21:56:54+00:00\",\"dateModified\":\"2026-02-18T21:56:56+00:00\",\"description\":\"Orforglipron for obesity is a new oral GLP-1 alternative that achieves significant weight loss without the need for injections.\",\"breadcrumb\":{\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#primaryimage\",\"url\":\"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg\",\"contentUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"Cinta de medicion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/fehv.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New drugs for weight loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fehv.org\/#website\",\"url\":\"https:\/\/fehv.org\/\",\"name\":\"Cl\u00ednica FEHV\",\"description\":\"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales\",\"publisher\":{\"@id\":\"https:\/\/fehv.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fehv.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fehv.org\/#organization\",\"name\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\",\"url\":\"https:\/\/fehv.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png\",\"contentUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png\",\"width\":47,\"height\":73,\"caption\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\"},\"image\":{\"@id\":\"https:\/\/fehv.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/pages\/Fundacion Para el Estudio de las Hepatitis Virales\/228605694153917\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777\",\"name\":\"ifranco\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g\",\"caption\":\"ifranco\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New drugs for weight loss - Cl\u00ednica FEHV","description":"Orforglipron for obesity is a new oral GLP-1 alternative that achieves significant weight loss without the need for injections.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/","og_locale":"en_US","og_type":"article","og_title":"New drugs for weight loss","og_description":"Orforglipron for obesity is a new oral GLP-1 alternative that achieves significant weight loss without the need for injections.","og_url":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/","og_site_name":"Cl\u00ednica FEHV","article_publisher":"https:\/\/www.facebook.com\/pages\/Fundacion%20Para%20el%20Estudio%20de%20las%20Hepatitis%20Virales\/228605694153917\/","article_published_time":"2026-02-18T21:56:54+00:00","article_modified_time":"2026-02-18T21:56:56+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg","type":"image\/jpeg"}],"author":"ifranco","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ifranco","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#article","isPartOf":{"@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/"},"author":{"name":"ifranco","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777"},"headline":"New drugs for weight loss","datePublished":"2026-02-18T21:56:54+00:00","dateModified":"2026-02-18T21:56:56+00:00","mainEntityOfPage":{"@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/"},"wordCount":295,"publisher":{"@id":"https:\/\/fehv.org\/#organization"},"image":{"@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg","articleSection":["Health","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/","url":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/","name":"New drugs for weight loss - Cl\u00ednica FEHV","isPartOf":{"@id":"https:\/\/fehv.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#primaryimage"},"image":{"@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg","datePublished":"2026-02-18T21:56:54+00:00","dateModified":"2026-02-18T21:56:56+00:00","description":"Orforglipron for obesity is a new oral GLP-1 alternative that achieves significant weight loss without the need for injections.","breadcrumb":{"@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#primaryimage","url":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/02\/nuevo-medicamentos-adelgazar.jpg","width":1920,"height":1280,"caption":"Cinta de medicion"},{"@type":"BreadcrumbList","@id":"https:\/\/fehv.org\/en\/new-drugs-for-weight-loss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fehv.org\/en\/"},{"@type":"ListItem","position":2,"name":"New drugs for weight loss"}]},{"@type":"WebSite","@id":"https:\/\/fehv.org\/#website","url":"https:\/\/fehv.org\/","name":"Cl\u00ednica FEHV","description":"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales","publisher":{"@id":"https:\/\/fehv.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fehv.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fehv.org\/#organization","name":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV","url":"https:\/\/fehv.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/","url":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","width":47,"height":73,"caption":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV"},"image":{"@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pages\/Fundacion Para el Estudio de las Hepatitis Virales\/228605694153917\/"]},{"@type":"Person","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777","name":"ifranco","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g","caption":"ifranco"}}]}},"_links":{"self":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4778"}],"collection":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/comments?post=4778"}],"version-history":[{"count":1,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4778\/revisions"}],"predecessor-version":[{"id":4779,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4778\/revisions\/4779"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media\/4776"}],"wp:attachment":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media?parent=4778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/categories?post=4778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/tags?post=4778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}